Home › Research › Prevention and risk
Blood Pressure, Antihypertensive Use, and Late-Life Alzheimer and Non-Alzheimer Dementia Risk: An Individual Participant Data Meta-Analysis
Lennon MJ, Lipnicki DM, Lam BCP, Crawford JD, Schutte AE, Peters R, et al.. Neurology, 2024-08-14
Topic: Risk, prevention and care in population studies
Plain-language summary
Background and objectives Previous randomized controlled trials and longitudinal studies have indicated that ongoing antihypertensive use in late life reduces all-cause dementia risk, but the specific impact on Alzheimer dementia (AD) and non-AD risk remains unclear. Results There were 31,250 participants from 14 nations in the analysis (41% male) with a mean baseline age of 72 (SD 7.5, range 60-110) years. Participants with untreated hypertension had a 36% (hazard ratio [HR] 1.36, 95% CI 1.01-1.83, p = 0.0406) and 42% (HR 1.42, 95% CI 1.08-1.87, p = 0.0135) increased risk of AD compared with "healthy controls" and those with treated hypertension, respectively. Compared with "healthy controls" both those with treated (HR 1.29, 95% CI 1.03-1.60, p = 0.0267) and untreated hypertension (HR 1.69, 95% CI 1.19-2.40, p = 0.0032) had greater non-AD risk, but there was no difference between the treated and untreated groups. Baseline diastolic BP had a significant U-shaped relationship ( p = 0.0227) with non-AD risk in an analysis restricted to those with 5-year follow-up, but otherwise there was no significant relationship between baseline BP and either AD or non-AD risk. Discussion Antihypertensive use was associated with decreased AD but not non-AD risk throughout late life. This suggests that treating hypertension throughout late life continues to be crucial in AD risk mitigation. A single measure of BP was not associated with AD risk, but DBP may have a U-shaped relationship with non-AD risk over longer periods in late life.
What this study adds
Evidence grade: Moderate
This is a pooled review of 31,250 participants. This individual participant data meta-analysis of 31,250 people found that antihypertensive use was associated with decreased Alzheimer dementia risk but not non-Alzheimer dementia risk throughout late life. Reported effect size: Untreated vs treated hypertension: Alzheimer's dementia HR 1.42 (95% CI 1.08-1.87).
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Lennon, M. J., Lipnicki, D. M., Lam, B. C. P., Crawford, J. D., Schutte, A. E., Peters, R., et al. (2024). Blood Pressure, Antihypertensive Use, and Late-Life Alzheimer and Non-Alzheimer Dementia Risk: An Individual Participant Data Meta-Analysis. Neurology. https://doi.org/10.1212/WNL.0000000000209715
Vancouver
Lennon MJ, Lipnicki DM, Lam BCP, Crawford JD, Schutte AE, Peters R, et al. Blood Pressure, Antihypertensive Use, and Late-Life Alzheimer and Non-Alzheimer Dementia Risk: An Individual Participant Data Meta-Analysis. Neurology. 2024. doi:10.1212/WNL.0000000000209715. PMID: 39141884.
BibTeX
@article{lennon2024-39141884,
author = {Lennon, M. J. and Lipnicki, D. M. and Lam, B. C. P. and Crawford, J. D. and Schutte, A. E. and Peters, R. and others},
title = {{Blood Pressure, Antihypertensive Use, and Late-Life Alzheimer and Non-Alzheimer Dementia Risk: An Individual Participant Data Meta-Analysis}},
journal = {Neurology},
year = {2024},
doi = {10.1212/WNL.0000000000209715},
pmid = {39141884},
url = {https://doi.org/10.1212/WNL.0000000000209715}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Background and objectives Previous randomized controlled trials and longitudinal studies have indicated that ongoing antihypertensive use in late life reduces all-cause dementia risk, but the specific impact on Alzheimer dementia (AD) and non-AD risk remains unclear.
- Results There were 31,250 participants from 14 nations in the analysis (41% male) with a mean baseline age of 72 (SD 7.5, range 60-110) years.
- Participants with untreated hypertension had a 36% (hazard ratio [HR] 1.36, 95% CI 1.01-1.83, p = 0.0406) and 42% (HR 1.42, 95% CI 1.08-1.87, p = 0.0135) increased risk of AD compared with "healthy controls" and those with treated hypertension, respectively.
- Compared with "healthy controls" both those with treated (HR 1.29, 95% CI 1.03-1.60, p = 0.0267) and untreated hypertension (HR 1.69, 95% CI 1.19-2.40, p = 0.0032) had greater non-AD risk, but there was no difference between the treated and untreated groups.
- Baseline diastolic BP had a significant U-shaped relationship ( p = 0.0227) with non-AD risk in an analysis restricted to those with 5-year follow-up, but otherwise there was no significant relationship between baseline BP and either AD or non-AD risk.
Why it matters
This individual participant data meta-analysis of 31,250 people found that antihypertensive use was associated with decreased Alzheimer dementia risk but not non-Alzheimer dementia risk throughout late life. It suggests that treating hypertension in late life remains important for reducing Alzheimer dementia risk, though it does not show a treatment or cure.
New to this subject? Start with our plain-English guide: Prevention →
Study details
- Study designmeta-analysis
- Participants31,250
- Effect sizeUntreated vs treated hypertension: Alzheimer's dementia HR 1.42 (95% CI 1.08-1.87)
- Evidence strengthModerate
Limitations
Observational cohorts with hypertension history partly self-reported; single baseline BP measurement; residual confounding by indication.
How this study scored 79/100
Published in a leading specialty journal, and it is a meta-analysis pooling many studies. We have no data on free to read, so that was left out: it earned 77 of the 98 points we could judge it on, which is 79 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Neurology) |
| Journal's citation record | 4 / 4 | Neurology: journal h-index 525 (OpenAlex, 2026-10-29) |
| Study design | 12 / 12 | A meta-analysis pooling many studies |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2024 — within 3 year(s) of the newest study here |
| Sample size | 4 / 4 | 31,250 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | A review of other studies — randomization is not credited here |
| Times cited | 4 / 7 | Cited 40 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 10.0 citations a year over 4 year(s) since 2024 |
| Impact for its field and year | 4 / 6 | Cited 10.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 4 other studies in this library |
| Still being cited | 2 / 4 | Cited 40 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Perminder Singh Sachdev: h-index 147 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Imperial College London: institution h-index 1,744 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 5 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 39141884) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 77 / 98 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 77 of the 98 points we could judge it on is 79 out of 100. |
| Total | 79 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1212/WNL.0000000000209715
- PubMed: 39141884
- Original source →
- Free full text: PubMed Central →
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 14.
Later studies that cite this one
4 studies in the alzhub library list this one in their references.
Related studies in Prevention and risk from nearby years
Also tagged “biobank”
1,084 studies in the library carry the topic tag “biobank”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,084 tagged studies.